IDH1 and intrahepatic cholangiocarcinoma: Based on these positive findings, both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency have approved ivosidenib for the treatment of adult patients with previously treated, locally advanced, or metastatic ICC carrying IDH1 mutations [7, 8].